{"prompt": "['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 153 of 169', 'Section number', 'Description of change', 'Brief rationale', 'and name', 'Section 6.1', 'The following endpoints have been added as', 'To evaluate the', 'Trial objectives and', 'other endpoints:', 'patient-reported outcomes', 'endpoints: Initial', 'HADS anxiety and HADS depression', 'and health care resource', 'treatment period of', 'scores <8 at Week 16 in subjects with', 'utilisation.', 'Weeks 0 to 16', 'baseline HADS anxiety or', 'HADS depression subscale scores of >8.', 'Reduction from baseline to Week 16 of', 'POEM of >4 points among subjects with', 'baseline POEM >4.', 'Section 6.2', 'IGA of 0/1 at Week 52 among subjects', 'To evaluate the', 'Trial objectives and', 'with IGA of 0/1 at Week 16 achieved', 'maintenance of effect', 'endpoints:', 'without rescue medication after initial', 'achieved with', 'Maintenance', 'randomisation to tralokinumab.', 'tralokinumab.', 'treatment period of', 'EASI75 at Week 52 among subjects with', 'Week 16 to 52 for', 'EASI75 at Week 16 achieved without', 'responders at', 'rescue medication after initial', 'Week 16', 'randomisation to tralokinumab.', 'IGA 0/1 or EASI75 at Week 52 among', 'subjects with IGA 0/1 or EASI75 at', 'Week 16 achieved without rescue', 'medication.', 'The maintenance endpoints of IGA 0/1 and', 'EASI75 at Week 52 for subjects achieving', 'clinical response at Week 16 without rescue', 'medication are considered secondary', 'endpoints.', 'In Japan, the maintenance endpoints of IGA', '0/1 and EASI75 at Week 52 for subjects', 'achieving clinical response at Week 16', 'without rescue medication are evaluated as', 'primary maintenance endpoints.', 'Section 7.1', 'A 16 14-week off treatment follow-up period', 'Clarification that the', 'Overall trial design', 'for the assessment of safety is also included', 'follow-up period has a', '(Weeks 52 to 66).', 'duration of 14 weeks since', 'the maintenance period', 'All subjects will complete a 1614-week off', 'and the open-label arm', 'both include the Week 52', 'treatment follow-up period for the assessment', 'visit. Since the last dose of', 'of safety and ADA at Week 66 (or Week 82).', 'IMP is administered at', 'Week 50 (or Week 66),', 'the follow-up visit will', 'occur 16 weeks after last', 'IMP administration.', 'eDoc-00631888 - Version 4.0']['Trial ID: LP0162-1325', 'Date: 14-Aug-2018', 'Version: 4.0', 'Page 154 of 169', 'Section number', 'Description of change', 'Brief rationale', 'and name', 'Section 7.1', 'Transfer to open-label may occur at any visit', 'Clarification that transfer', 'Overall trial design', 'while the subject is in the maintenance', 'to open-label requires a', 'treatment period but no earlier than', 'persistent worsening of', 'Week 22.', 'disease observed over', '3 consecutive visits in the', 'maintenance period.', 'Section 8.2', 'Worst Daily Pruritus NRS at baseline will be', 'Clarification of how Worst', 'Inclusion criteria', 'calculated from daily assessments of worst itch', 'Daily Pruritus NRS at', '(no. 9)', 'severity (Worst Daily Pruritus NRS) during the', 'baseline will be calculated.', '7 days immediately preceding randomisation', '(Day -6 to 0).', 'Inclusion criteria', 'The subjects must have used the contraceptive', 'Clarification that female', '(no. 11)', 'method continuously for at least 1 month prior', 'subjects of childbearing', 'to the pregnancy test at baseline.', 'potential must have used a', 'highly effective form of', 'birth control for at least', '1 month prior to baseline.', 'Section 10.5.2.2', 'All subjects will have blood samples taken for', 'Clarification that the small', 'Small biomarker', 'analysis of a small panel of biomarkers. The', 'biomarker panel may', 'panel (all subjects)', 'biomarkers to be analysed include, but are', 'include more than', 'not limited to, the following: (periostin,', '7 biomarkers.', 'DPP4, CCL17 (also known as thymus and', 'activation regulated chemokine [TARC]),', 'IL-13, IL-17, IL-22, and beta-defensin 4A', 'E(DEFB4A]).', 'Section 10.5.3', 'Histology/immunohistochemistry/in-situ', 'Neutrophils will not be', 'Skin biopsies', 'hybridisation', 'analysed because', '(selected trial sites)', 'T cells (e.g., CD3+ and CD8+), dendritic', 'neutrophil levels are not', 'cells (e.g., CD11c+, FccR1),', 'expected to change.', 'monocytes/macrophages (e.g., CD68),', 'neutrophils (e.g., myeloperoxidase),', 'epidermal markers (e.g., epidermal', 'thickness, keratin type I cytoskeletal 16,', 'proliferation marker protein Ki 67, protein', 'S100 A, filaggrin, loricrin).', 'Section 11.5.6', 'Any clinically significant aggravation/', 'Clarification that AE', 'Aggravation of', 'exacerbation/worsening of any medical', 'reporting starts at', 'condition', 'condition(s), compared to baseline screening,', 'screening, not baseline.', 'must be reported as an AE.', 'This is in alignment with', 'the information given in', 'Section 11.1 and', 'Appendix 4D.', 'eDoc-00631888 - Version 4.0']\n\n###\n\n", "completion": "END"}